The global spread of the COVID-19 pandemic and the resulting economic impact and public health burden has highlighted the urgent need for a vaccine to prevent the disease. The challenges associated with rapidly developing and producing a vaccine at a large scale are, however, enormous.<\/p>\n
Verdict has conducted a poll to assess the time that could be taken for the approval of a COVID-19 vaccine and its availability to the public.<\/p>\n
Analysis of the results shows a high chance for an approved COVID-19 vaccine to be available over the next six months, as opined by a majority 36% of the poll respondents, whereas 28% of the respondents feel it could take six to 12 months for the same.<\/p>\n
Less than one-fourth (22%) of the poll respondents opined that the approval and availability of a COVID-19 vaccine could take between 12 and 18 months, while 14% felt that it could take more than 18 months. <\/p>\n
The analysis is based on 875 responses received from readers of Verdicts Pharmaceutical Technology site between 18 June and 01 July.<\/p>\n<\/p>\n
The poll findings are in line with those of another poll conducted by Verdict earlier in April, which found high confidence about the possible development of a COVID-19 vaccine within 12 months. <\/p>\n
Research organisations and pharmaceutical companies have joined hands in developing a vaccine against the COVID-19 virus that has affected millions of people.<\/p>\n
Existing drugs such as remdesivir have been granted emergency use authorisation (EUA) to treat the disease, meanwhile.<\/p>\n
Antimalarial drugs including chloroquine and hydroxychloroquine were also awarded EUA, but later revoked after studies showed that they were ineffective in treating the disease.<\/p>\n
In another poll conducted on Pharmaceutical Technology site, Verdict tried to assess readers opinion about who should be given priority access to a COVID-19 vaccine upon licensure.<\/p>\n
The poll options included three groups namely those with high-risk such as the elderly and patients with co-morbidities, everyone, and those in high-risk geographies from infection.<\/p>\n
A majority 46% of the respondents opined that elderly and people with co-morbidities should be given priority access, followed by 33% who opined that everyone should have the same access to the vaccine.<\/p>\n
Prioritising the vaccines accessibility to high-risk geographies is of high importance for just 21% of the respondents.<\/p>\n<\/p>\n
The analysis is based on 354 responses received between 18 June and 08 July.<\/p>\n
Eight vaccines are in phase three\/two clinical trials currently, while another 120 are in pre-clinical evaluation, according to the World Health Organization (WHO).<\/p>\n
The vaccines that have reached advanced clinical trials include ChAdOx1-S by University of Oxford and AstraZeneca, an adenovirus type 5 vector vaccine by CanSino Biological and Beijing Institute of Biotechnology, mRNA-1273 vaccine by Moderna, and National Institute of Allergy and Infectious Diseases.<\/p>\n
Sinopharm is collaborating with the Wuhan Institute of Biological Products and Beijing Institute of Biological Products to develop an inactivated vaccine.<\/p>\n
Sinovac is developing an inactivated vaccine with alum and Novavax is developing a full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine, while BioNTech, Fosun Pharma, and Pfizer are developing a vaccine based on 3 LNP-mRNAs. <\/p>\n
<\/p>\n
See the rest here: The global spread of the COVID-19 pandemic and the resulting economic impact and public health burden has highlighted the urgent need for a vaccine to prevent the disease. The challenges associated with rapidly developing and producing a vaccine at a large scale are, however, enormous Continue reading
\nGene therapy innovations: Sarepta and Codiak partner on exosomes - Pharmaceutical Technology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"